Eltrombopag Meets Primary Endpoint In Phase 3 PETIT2 Study - Quick Facts

(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) announced that its partner, GlaxoSmithKline plc (GSK.L, GSK), presented the results from the Phase 3 PETIT2 study evaluating the efficacy of eltrombopag vs. placebo in pediatric patients with chronic immune (idiopathic) thrombocytopenic purpura (cITP). Eltrombopag met its primary endpoint, achieving a statistically significant improvement in platelet counts with almost 40 percent of patients treated with eltrombopag attaining a consistent platelet response for 6 of 8 weeks compared to placebo. Efficacy results for PETIT2 were consistent across age cohorts. The safety profile was consistent with the established profile for eltrombopag and no new safety concerns were observed.

GlaxoSmithKline also announced that it is moving forward with planned regulatory submissions for a pediatric indication in cITP later this year.